Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 2
2003 3
2004 12
2005 23
2006 31
2007 47
2008 46
2009 54
2010 57
2011 56
2012 64
2013 58
2014 58
2015 57
2016 45
2017 31
2018 46
2019 38
2020 48
2021 47
2022 38
2023 37
2024 23
2025 34
2026 20

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

809 results

Results by year

Filters applied: . Clear all
Page 1
Mindfulness-Based Stress Reduction vs Escitalopram for the Treatment of Adults With Anxiety Disorders: A Randomized Clinical Trial.
Hoge EA, Bui E, Mete M, Dutton MA, Baker AW, Simon NM. Hoge EA, et al. JAMA Psychiatry. 2023 Jan 1;80(1):13-21. doi: 10.1001/jamapsychiatry.2022.3679. JAMA Psychiatry. 2023. PMID: 36350591 Free PMC article. Clinical Trial.
OBJECTIVE: To determine whether MBSR is noninferior to escitalopram, a commonly used first-line psychopharmacological treatment for anxiety disorders. ...Secondary intent-to-treat analyses using imputed data also showed the noninferiority of MBSR compared with escitalop …
OBJECTIVE: To determine whether MBSR is noninferior to escitalopram, a commonly used first-line psychopharmacological treatment for a …
Trial of Psilocybin versus Escitalopram for Depression.
Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, Martell J, Blemings A, Erritzoe D, Nutt DJ. Carhart-Harris R, et al. N Engl J Med. 2021 Apr 15;384(15):1402-1411. doi: 10.1056/NEJMoa2032994. N Engl J Med. 2021. PMID: 33852780 Clinical Trial.
METHODS: In a phase 2, double-blind, randomized, controlled trial involving patients with long-standing, moderate-to-severe major depressive disorder, we compared psilocybin with escitalopram, a selective serotonin-reuptake inhibitor, over a 6-week period. Patients were as …
METHODS: In a phase 2, double-blind, randomized, controlled trial involving patients with long-standing, moderate-to-severe major depressive …
Increased global integration in the brain after psilocybin therapy for depression.
Daws RE, Timmermann C, Giribaldi B, Sexton JD, Wall MB, Erritzoe D, Roseman L, Nutt D, Carhart-Harris R. Daws RE, et al. Nat Med. 2022 Apr;28(4):844-851. doi: 10.1038/s41591-022-01744-z. Epub 2022 Apr 11. Nat Med. 2022. PMID: 35411074 Clinical Trial.
The second trial was a double-blind phase II randomized controlled trial comparing psilocybin therapy with escitalopram. Patients with major depressive disorder received either 2 25 mg oral psilocybin, 3 weeks apart, plus 6 weeks of daily placebo ('psilocybin arm') or 2 …
The second trial was a double-blind phase II randomized controlled trial comparing psilocybin therapy with escitalopram. Patients wit …
The safety and efficacy of escitalopram and sertraline in post-stroke depression: a randomized controlled trial.
Yan N, Hu S. Yan N, et al. BMC Psychiatry. 2024 May 15;24(1):365. doi: 10.1186/s12888-024-05833-w. BMC Psychiatry. 2024. PMID: 38750479 Free PMC article. Clinical Trial.
OBJECTIVES: This study aims to evaluate the safety and efficacy of escitalopram and sertraline in post-stroke depression (PSD) patients, to provide more reliable therapeutics for cardiovascular and psychiatric clinical practice. ...In addition, escitalopram was more …
OBJECTIVES: This study aims to evaluate the safety and efficacy of escitalopram and sertraline in post-stroke depression (PSD) patien …
Effectiveness of Escitalopram and Nortriptyline on Depressive Symptoms in Parkinson's disease: the ADepT-PD RCT pilot.
Schrag A, Carroll C, Lewis G, Serfaty M, Duncan G, Molloy S, Whipps J, McLennan B, Weng JYJ, Hunter RM, Clarke CS, Freemantle N, Embleton-Thirsk A. Schrag A, et al. Health Technol Assess. 2025 Nov;29(57):1-78. doi: 10.3310/HFDO7575. Health Technol Assess. 2025. PMID: 41217862 Free PMC article. Clinical Trial.
Four hundred and eight patients with a 1 : 1 : 1 randomisation between placebo, nortriptyline and escitalopram. The pilot study aimed to recruit 46 participants in the first 6 months from 10 sites to decide whether the trial is feasible. ...RESULTS: Fifty-two patients were …
Four hundred and eight patients with a 1 : 1 : 1 randomisation between placebo, nortriptyline and escitalopram. The pilot study aimed …
A Multicenter Double-Blind, Placebo-Controlled Trial of Escitalopram in Children and Adolescents with Generalized Anxiety Disorder.
Strawn JR, Moldauer L, Hahn RD, Wise A, Bertzos K, Eisenberg B, Greenberg E, Liu C, Gopalkrishnan M, McVoy M, Knutson JA. Strawn JR, et al. J Child Adolesc Psychopharmacol. 2023 Apr;33(3):91-100. doi: 10.1089/cap.2023.0004. J Child Adolesc Psychopharmacol. 2023. PMID: 37074330 Free article. Clinical Trial.
Vital signs, weight, laboratory, and electrocardiographic results were consistent with previous pediatric studies of escitalopram. Conclusions: Escitalopram reduced anxiety symptoms and was well tolerated in pediatric patients with GAD. These findings confirm earlie …
Vital signs, weight, laboratory, and electrocardiographic results were consistent with previous pediatric studies of escitalopram. Co …
Escitalopram in Adolescents With Generalized Anxiety Disorder: A Double-Blind, Randomized, Placebo-Controlled Study.
Strawn JR, Mills JA, Schroeder H, Mossman SA, Varney ST, Ramsey LB, Poweleit EA, Desta Z, Cecil K, DelBello MP. Strawn JR, et al. J Clin Psychiatry. 2020 Aug 25;81(5):20m13396. doi: 10.4088/JCP.20m13396. J Clin Psychiatry. 2020. PMID: 32857933 Free PMC article. Clinical Trial.
Vital signs, corrected QT interval, and adverse events were similar in patients who received escitalopram and placebo. CONCLUSIONS: Escitalopram reduces anxiety symptoms, and pharmacogenetics variables influence the trajectory and magnitude of improvement. Variation …
Vital signs, corrected QT interval, and adverse events were similar in patients who received escitalopram and placebo. CONCLUSIONS: …
Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects.
Becker AM, Holze F, Grandinetti T, Klaiber A, Toedtli VE, Kolaczynska KE, Duthaler U, Varghese N, Eckert A, Grünblatt E, Liechti ME. Becker AM, et al. Clin Pharmacol Ther. 2022 Apr;111(4):886-895. doi: 10.1002/cpt.2487. Epub 2021 Nov 22. Clin Pharmacol Ther. 2022. PMID: 34743319 Free PMC article. Clinical Trial.
Escitalopram did not alter the pharmacokinetics of psilocin. The half-life of psychoactive free (unconjugated) psilocin was 1.8 hours (range 1.1-2.2 hours), consistent with the short duration of action of psilocybin. Escitalopram did not alter HTR2A or SCL6A4 gene e …
Escitalopram did not alter the pharmacokinetics of psilocin. The half-life of psychoactive free (unconjugated) psilocin was 1.8 hours …
Efficacy and Safety of Hormone Replacement Combined With Escitalopram in the Treatment of Chronic Insomnia in Perimenopausal Women: A Randomized Controlled Trial.
Chen H, Wu S, Chen H, Zeng G, Wu W, Chen X, Chen X, Chen R, Xiao Y. Chen H, et al. CNS Neurosci Ther. 2025 Jun;31(6):e70470. doi: 10.1111/cns.70470. CNS Neurosci Ther. 2025. PMID: 40509584 Free PMC article. Clinical Trial.
AIMS: To explore the efficacy of Femoston plus escitalopram for perimenopausal women with chronic insomnia and the relevant biomarkers. METHODS: A total of 166 patients randomly received: escitalopram plus placebo (Escitalopram Group), Femoston plus placebo ( …
AIMS: To explore the efficacy of Femoston plus escitalopram for perimenopausal women with chronic insomnia and the relevant biomarker …
Running therapy or antidepressants as treatments for immunometabolic depression in patients with depressive and anxiety disorders: A secondary analysis of the MOTAR study.
Vreijling SR, Penninx BWJH, Verhoeven JE, Teunissen CE, Blujdea ER, Beekman ATF, Lamers F, Jansen R. Vreijling SR, et al. Brain Behav Immun. 2025 Jan;123:876-883. doi: 10.1016/j.bbi.2024.10.033. Epub 2024 Oct 28. Brain Behav Immun. 2025. PMID: 39477079 Free article. Clinical Trial.
METHODS: Participants received 16 weeks of group-based running therapy (N = 96) or escitalopram/sertraline (N = 45) in a partially randomized patient preference design. IMD features included atypical, energy-related symptom (AES) severity, inflammation index (CRP, IFN-gamm …
METHODS: Participants received 16 weeks of group-based running therapy (N = 96) or escitalopram/sertraline (N = 45) in a partially ra …
809 results